

## **SUMMARY OF INTERVIEW**

### Attendees, Date and Type of Interview

The interview was conducted on March 2, 2009 and attended by Examiner Daniel C. Gamett and Applicants' representatives Daniel E. Altman and Raymond D. Smith.

### Exhibits and/or Demonstrations

None

### Identification of Claims Discussed

Claims 1 and 28-31.

### Identification of Prior Art Discussed

N/A

### Proposed Amendments

Claim 1: Removal of the expression: "for isolating and/or identifying at least one cell population which is selected from the group consisting of haematopoietic tem cells, neuronal stem cells, neuronal progenitor cells, mesenchymal stem cells and mesenchymal progenitor cells."

Claims 28-31: Redrafting Claims 28-31 as independent claims.

### Principal Arguments and Other Matters

Claim 1: The claimed monoclonal antibodies are novel, and therefore patentable, regardless of an intended use.

Claims 28-31: Under 35 U.S.C. § 112, paragraph 4, a claim that refers back to another claim must incorporate all of the limitations of that claim. Since the recited fragments in Claims 28-31 do not incorporate the parts of the monoclonal antibody not included within the fragments, the claims might be read as improper.

### Results of Interview

The Examiner agreed that the amendments should be acceptable to enter after allowance as they do not materially change the scope of the claims.